Holen Sie sich die Stockscreener-App
198.73
1.44%
-4.4649
Schlusskurs vom Vortag:
$203.19
Offen:
$205.47
24-Stunden-Volumen:
974.21K
Relative Volume:
0.71
Marktkapitalisierung:
$28.47B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-121.09
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+2.15%
1M Leistung:
-1.72%
6M Leistung:
-15.55%
1J Leistung:
+30.61%
1-Tages-Spanne:
$198.60
$209.00
1-Wochen-Bereich:
$197.16
$210.67
52-Wochen-Spanne:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
198.78 | 29.10B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
449.03 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
173.03 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.96 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
339.70 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.52 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera Expands Austin Operations With New Sequencing Facility - Yahoo Finance
Natera enhances prenatal test, cuts no-call rate to 0.5% - Investing.com
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology - Yahoo Finance
(NTRA) Risk Channels and Responsive Allocation - Stock Traders Daily
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Natera, Inc. (NTRA) Stock Analysis: Riding High On A 28.4% Potential Upside - DirectorsTalk Interviews
What's Driving Natera's Recent Stock Action - Kavout
How The Natera (NTRA) Investment Story Is Shifting With New Guidance And Analyst Revisions - Yahoo Finance
Is It Time To Reconsider Natera (NTRA) After Its Strong Five Year Share Price Gain - simplywall.st
NTRA Stock Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology - BioSpace
Natera to present 35 oncology abstracts at ASCO meeting By Investing.com - Investing.com South Africa
Natera to present 35 oncology abstracts at ASCO meeting - Investing.com UK
Mid-Cap Stocks Analysis: Natera to Buy, Graco and Jacobs Solutions to Sell | StockStoryNews and Statistics - IndexBox
35 Natera studies test ctDNA to flag cancer return at ASCO - Stock Titan
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $220 to $285 - Moomoo
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone - The Globe and Mail
Natera announces expansion into Austin, creating largest sequencing factory - TipRanks
Natera Expands Operations in Austin - Moomoo
Natera expands Austin facility, plans to add 400 jobs - Investing.com
Natera expands Austin facility, plans to add 400 jobs By Investing.com - Investing.com Canada
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World - Yahoo Finance
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling? - Kavout
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Expands Clinical Trial Enrollment to Over 2,000 Pa - GuruFocus
Natera Expands Enrollment in Fetal Genetic Testing Study - Moomoo
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Natera’s EXPAND trial enrolls over 2,000 patients - Investing.com UK
Natera’s EXPAND trial enrolls over 2,000 patients By Investing.com - Investing.com Australia
Study of prenatal gene risk test now passes 2,000 patients - Stock Titan
Quinn Emanuel Owes More Sanctions In Guardant Fight - Law360
FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera (NTRA) - simplywall.st
Is It Time To Reassess Natera (NTRA) After The Recent Share Price Pullback - Yahoo Finance
Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancer - Quiver Quantitative
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer - The Globe and Mail
Natera wins FDA approval for companion diagnostic - MedTech Dive
What's Behind Natera CEO Steven Chapman's Recent Stock Sales - Kavout
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call - Yahoo Finance
A Look At Natera (NTRA) Valuation After Recent Share Price Weakness - simplywall.st
Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Natera, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman - GuruFocus
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors - AD HOC NEWS
Natera Scores Rare FDA Approval but Shares Drop - TechStock²
Natera co-founder Sheena Jonathan sells $959,450 in company stock - Investing.com India
Natera co-founder Sheena Jonathan sells $959,450 in company stock By Investing.com - Investing.com UK
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans - Stock Titan
New blood test helps tailor bladder cancer treatment, wins FDA backing - Stock Titan
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod - Fierce Pharma
Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer - Moomoo
Natera Gets FDA Approval for Bladder-Cancer Test - marketscreener.com
Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake - The Daily Upside
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
May 13 '26 |
Sale |
201.56 |
1,500 |
302,347 |
19,532 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 05 '26 |
Sale |
213.77 |
6,986 |
1,493,363 |
2,376,402 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 04 '26 |
Sale |
206.16 |
722 |
148,848 |
2,382,440 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 04 '26 |
Sale |
210.49 |
482 |
101,456 |
57,496 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 01 '26 |
Sale |
206.16 |
313 |
64,528 |
57,978 |
| Sheena Jonathan | CO-FOUNDER |
May 01 '26 |
Sale |
206.16 |
107 |
22,059 |
255,652 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
May 01 '26 |
Sale |
203.69 |
3,405 |
693,560 |
142,295 |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
May 01 '26 |
Sale |
206.16 |
291 |
59,993 |
187,220 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
May 01 '26 |
Sale |
206.16 |
902 |
185,956 |
149,867 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
May 01 '26 |
Sale |
206.16 |
330 |
68,033 |
222,694 |
1.75%
0.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):